Immunotherapy company Biopharmaceutical New Technologies or BioNTech SE (BNTX) reported Tuesday a net loss of 531.9 million euros or 2.10 euros per share for the first quarter, wider than 415.8 million euros or 1.73 euros per share in the prior-year quarter.
Excluding items, adjusted net loss for the quarter was 1.95 euros per share, compared to adjusted net loss of 1.79 euros per share in the year-ago quarter.
Total revenues for the quarter decreased to 118.1 million euros from 182.8 million euros in the same quarter last year, primarily driven by lower revenues of BioNTechs COVID-19 vaccines.
Looking ahead to fiscal 2026, the company continues to project revenues between 2.0 billion to 2.3 billion euros.
BioNTech also said it anticipates lower COVID-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets.
The Management Board and Supervisory Board also expect to authorize a share repurchase program of BioNTechs American Depositary Shares (ADSs), pursuant to which the Company may repurchase ADSs in the amount of up to $1.0 billion over the next twelve months.
The program is designed to enhance capital efficiency and support long-term value creation to execute BioNTechs objective to become a multi-product company by 2030.
In Tuesday's pre-market trading, BNTX is trading on the Nasdaq at $96.70, down $2.65 or 2.67 percent.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.